Kontafarma Expects Loss Despite Revenue Growth

Kontafarma China Holdings Ltd (HK:1312) has released an update.

Kontafarma China Holdings Limited has issued a profit warning, revealing an expected consolidated net loss of HK$4 million to HK$8 million for the first half of 2024. This comes in stark contrast to their net profit of HK$21.4 million in the same period last year, mainly due to the absence of a one-off gain from subsidiary disposals. Despite the loss, the company anticipates increased revenue and gross profit in its core pharmaceutical and fitness segments, alongside reduced expenses from effective cost control measures.

For further insights into HK:1312 stock, check out TipRanks’ Stock Analysis page.